Toll Free: 1-888-928-9744

Medicago Inc. - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Medicago Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Medicago Inc. - Product Pipeline Review - 2014', provides an overview of the Medicago Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Medicago Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Medicago Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Medicago Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Medicago Inc.'s pipeline products

Reasons to buy

- Evaluate Medicago Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Medicago Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Medicago Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Medicago Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Medicago Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Medicago Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Medicago Inc. Snapshot 5
Medicago Inc. Overview 5
Key Information 5
Key Facts 5
Medicago Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Medicago Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Medicago Inc. - Pipeline Products Glance 12
Medicago Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Medicago Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Medicago Inc. - Drug Profiles 16
influenza [H1N1] (quadrivalent) (virus like particle) vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
influenza [H5N1] (virus like particle) vaccine + Glucopyranosyl Lipid A Adjuvant 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
influezna [H5N1] (virus like particles) vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
influenza [H7N9] (virus like particles) vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Biosimilar for Infectious Diseases 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
influenza (virus like particles) vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
influenza [H7N9] (virus like particle) vaccine + Glucopyranosyl Lipid A Adjuvant 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
rabies (virus like particles) vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
rotavirus (virus like particles) vaccine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
VLP Vaccine 1 for Infectious Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ebola (virus like particles) vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
VLP Vaccine 2 for Infectious Diseases 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Medicago Inc. - Pipeline Analysis 31
Medicago Inc. - Pipeline Products by Route of Administration 31
Medicago Inc. - Pipeline Products by Molecule Type 32
Medicago Inc. - Recent Pipeline Updates 33
Medicago Inc. - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40
List of Tables
Medicago Inc., Key Information 5
Medicago Inc., Key Facts 5
Medicago Inc. - Pipeline by Indication, 2014 8
Medicago Inc. - Pipeline by Stage of Development, 2014 9
Medicago Inc. - Monotherapy Products in Pipeline, 2014 10
Medicago Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Medicago Inc. - Phase II, 2014 12
Medicago Inc. - Phase I, 2014 13
Medicago Inc. - Preclinical, 2014 14
Medicago Inc. - Discovery, 2014 15
Medicago Inc. - Pipeline by Route of Administration, 2014 31
Medicago Inc. - Pipeline by Molecule Type, 2014 32
Medicago Inc. - Recent Pipeline Updates, 2014 33
Medicago Inc., Other Locations 38
Medicago Inc., Subsidiaries 38 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify